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Dominant transmission of multiple uterine and cutaneous smooth-muscle tumors is seen in the disorder multiple
leiomyomatosis (ML). We undertook a genomewide screen of 11 families segregating ML and found evidence for
linkage to chromosome 1q42.3-q43 (maximum multipoint LOD score 5.40). Haplotype construction and analysis
of recombinations permitted the minimal interval containing the locus, which we have designated “MCUL1,” to
be refined to an ∼14-cM region flanked by markers D1S517 and D1S2842. Allelic-loss studies of tumors indicated
that MCUL1 may act as a tumor suppressor. Identification of MCUL1 should have wide interest, since this gene
may harbor low-penetrance variants predisposing to the common form of uterine fibroids and/or may undergo
somatic mutation in sporadic leiomyomata.
Uterine fibroids, or leiomyomata, are the most common
tumors in women during the reproductive years, yet little
is known about their etiology. In most countries, they are
the most frequent indication for hysterectomy in pre-
menopausal women and therefore present a major public
health issue. In addition to environmental and lifestyle
factors, there is evidence that inherited factors play a role.
Evidence supporting genetic predisposition to leiomyo-
mata comes both from case reports of families with dis-
ease (Vikhlyaeva et al. 1995) and from population-based
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studies (Kurbanova et al. 1989a). Average estimates of
familial risk are ∼25% in the first-degree relatives of af-
fected probands, and, on the basis of the recurrence rate
in siblings, estimates of the heritability of uterine leiomyo-
mata are .26–.80 (Kurbanova et al. 1989b; Snieder et al.
1998; Luoto et al. 2000).
Genetic predisposition to fibroids is undoubtedly het-
erogeneous. Dominant transmission of uterine myomata
is, however, seen in the rare disorder multiple leiomy-
omatosis (ML [MIM 150800]) (Mezzadra 1965; Rudner
et al. 1972; Reed et al. 1973; Engelke and Christophers
1979; Guillet et al. 1987); ∼15 such families have been
reported in the world literature. In this disorder, females
develop both multiple skin leiomyomata and multiple
uterine fibroids; males develop the skin lesions. The fi-
broids in patients with ML tend to be of variable size
but are usually of early onset and are reportedly similar
to the very common sporadic lesions. They may be com-
plicated by anemia and/or subfertility, requiring my-
omectomy or hysterectomy. Although uncommon, ma-
Figure 1 Pedigrees of families studied. Left-half-blackened symbols indicate individuals with cutaneous leiomyomata; right-half-blackened
symbols indicate individuals with uterine fibroids. Unaffected, untyped individuals (except spouses) are not shown. Numbered genotypes are
shown at markers D1S517, D1S2785, D1S547, D1S404, D1S180, and D1S2842 (listed from top to bottom, in 1cen-qter order). A question
mark (?) denotes untyped or failed typing; the thicker black bars indicate the chromosome 1q42.3-q43 haplotype shared by affected individuals.
In family 123, note that, although the affected siblings could share alleles at untyped markers D1S180 and D1S2842 (if a recombination has
occurred within this region), haplotypes below D1S2842 (not shown) make this unlikely.
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Table 1
Two-Point LOD Scores in Families in the Present Study
A. LOD Scores at vp .001
FAMILY
LOD SCORE FOR
D1S517 D1S2785 D1S547 D1S404 D1S180 D1S2842
14 .30 .30 .30 .30 .00 .00
123 2.15 .00 0.45 1.01 .00 .00
136 .30 .60 .60 .00 .60 .30
296 0.05 .00 0.10 0.14 .00 .00
297 0.05 .00 .00 .56 .00 2.04
304 2.65 .34 1.30 1.69 1.32 1.02
333 .10 .09 .10 .08 .00 .05
841 .30 .30 .00 .26 .00 .00
3171 .36 .49 .39 .13 .14 2.28
3172 .23 .23 .09 .22 .20 .22
7651 .10 .05 .19 .15 .09 .21
Total 3.61 2.12 1.84 2.08 2.17 2.62
B. LOD Scores at D1S2785, for Various Values of v
FAMILY
LOD SCORE FOR v p
.001 .01 .05 .10 .20 .30 .40
14 .30 .29 .26 .21 .13 .06 .02
123 .00 .00 .00 .00 .00 .00 .00
136 .60 .59 .53 .47 .34 .21 .10
296 .00 .00 .00 .00 .00 .00 .00
297 .00 .00 .00 .00 .00 .00 .00
304 .34 1.03 1.41 1.38 1.04 .61 .23
333 .09 .09 .07 .06 .03 .01 .00
841 .30 .30 .28 .25 .20 .15 .08
3171 .49 .47 .41 .33 .19 .08 .02
3172 .23 .22 .20 .16 .10 .05 .01
7651 .05 .05 .04 .03 .02 .01 .00
Total 2.12 2.76 2.98 2.71 1.95 1.14 .46
lignant transformation of uterine lesions has been
reported (Reed et al. 1973). The skin leiomyomata occur
superficially in the dermis and are thought to arise from
the erector pili muscles of the hair follicle. The skin le-
sions are smooth and shiny, tend to be 0.2–2 cm in
diameter, and may be painful, especially in heat or cold
or when subjected to pressure.
A small number of candidate loci for ML exist. Alport
syndrome (AS [MIM 301050, MIM 104200, MIM
203780, andMIM 308940]) can be caused bymutations
of collagen genes, including loci on Xq22.3 and 2q36-
2q37. AS is associated not only with multiple leiomy-
omata, particularly of the esophagus, but also with other
specific clinical features (see the Online Mendelian In-
heritance in Man website). A patient without AS but
with multiple cutaneous leiomyomata has been reported
(Fryns et al. 1985) to carry constitutional 9p trisomy/
18p distal monosomy.
We have ascertained 11 families with dominantly in-
herited cutaneous and uterine leiomyomata and have
performed a genomewide screen to detect the location
of the ML gene. Pedigrees were ascertained through der-
matologists throughout the United Kingdom. Patient in-
formation, histology reports, and samples were obtained
with full informed consent and ethical-review-board ap-
proval. Details of affection status were derived either
from personal examination or from histopathology re-
ports and medical records and, wherever possible, were
confirmed by histological review of tumors. Fresh-frozen
samples were obtained from eight cutaneous leiomy-
omata from the families. DNA was extracted from pe-
ripheral blood and tumor samples by standard methods.
To map the position of the ML gene, an initial 10–15-
cM genomewide linkage search was undertaken, using
fluorescence-labeled oligonucleotide markers taken from
the Weber 9a set (Research Genetics). Dye-labeled PCR
products were detected on ABI 377 DNA sequencers and
were analyzed by GENESCAN and GENOTYPER soft-
ware (Applied Biosystems). Additional polymorphic
markers were taken from The Genetic Location Data-
base map.
ML was modeled as a dominant trait with a gene
frequency of .001. Only individuals with skin lesions
were classified as affected. Individuals with uterine fi-
broids but without skin lesions were classified as un-
known, to take account of the population prevalence of
uterine fibroids and, hence, the relatively high proba-
bility of phenocopies from this source. Individuals with-
out skin lesions who married into the family were clas-
sified as unaffected. All other family members were
classified as unknown. A .001 phenocopy rate for mul-
tiple cutaneous leiomyomata was assumed. Two-point
LOD scores were calculated for each marker, by the sub-
program MLINK (version 5.1) of the LINKAGE pro-
gram package (Lathrop et al. 1984) as implemented in
FASTLINK (version 4.1) (O’Connell and Weeks 1995).
Multipoint analyses were undertaken, by means of the
VITESSE program (Cottingham et al. 1993). Marker-
allele frequencies were either taken from The Genome
Database or based on the genotyping of pedigree foun-
ders. The map order and distances between markers
were based on the integrated map of The Genetic Lo-
cation Database.
The 11 families (fig. 1) consisted of 54 affected in-
dividuals, and DNA samples were obtained from 44 of
these. In brief, skin lesions presented at an age between
the early teens and the 4th decade and tended to occur
in crops on the trunk and limbs. All patients studied
were 118 years old (median 47 years, range 28–91
years). Most patients reported that one or more lesions,
especially larger ones, were painful in heat or cold. Be-
tween individuals, there was notable variation in the
number of skin lesions. Of the 36 females affected by
skin leiomyomata, 33 reported a history of fibroids (fig.
1); in all cases, these fibroids were confirmed as multiple
lesions, some of which measured only a few millimeters
in diameter.
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Figure 2 Multipoint linkage analysis with 1q42.3-q43 markers. The X-axis shows the marker location on chromosome 1, and the Y-axis
shows the LOD score.
Figure 3 Loss of wild-type allele (arrow) at D1S2842 in skin
leiomyoma from individual 301 from family 297.
The initial genome screen detected eight regions with
two-point LOD scores 11, with a maximum score of 1.84
(recombination fraction [v] .001) at marker D1S547
(1q42.3-q43). Additional typing of markers in these eight
regions formally excluded all but the region near D1S547
(details not shown). A maximum two-point LOD score
of 2.99 (table 1) was obtained with marker D1S2785
( ). By means of a sliding map of three markers,vp .04
multipoint LOD scores were calculated across the re-
gion aroundD1S547 andD1S2785. Themaximummulti-
point LOD score obtained was 5.40, for the markers
D1S2785–3.2 cM–D1S547–0.01 cM–D1S404 (fig. 2). In
family 304 alone, the maximum multipoint LOD score
obtained was 3.97 at D1S404, for these same markers.
Haplotype construction showed that, except for ped-
igree 123 (fig. 1), all the families studied were compatible
with linkage of ML to chromosome 1q42.3-q43. When
data from this family were excluded, haplotype analysis
placed the predisposition gene, which we have termed
“MCUL1” (multiple cutaneous and uterine leiomy-
omata 1), within an ∼14-cM interval bounded, on the
centromeric side, by D1S517 and, on the telomeric side,
by D1S2842. Both the critical recombinations defining
this region occurred in the large family, 304. As ex-
pected, we found in the 14-cM region no good evidence
of haplotype sharing between families.
Of 33 females with the disease-associated haplotype,
25 had both skin leiomyomata and uterine fibroids, 3
had skin leiomyomata only (although occult fibroids
were not excluded), 1 (a member of family 304, who
was age 33 years at the time of the study) had uterine
fibroids only, and 4 (who were ages 28, 34, 35, and 67
years at the time of the study) were unaffected. One
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female (a member of family 14) with uterine fibroids did
not share the disease-associated haplotype and had de-
veloped an unknown number of fibroids during her late
40s; she presumably represents a sporadic case. Of 16
males who had the disease-associated haplotype, 13 had
developed skin leiomyomata; the unaffected carriers
were ages 33, 35, and 36 years. The disease gene ap-
peared, therefore, to have high penetrance.
Genotyping for allelic loss in the skin leiomyomata
was performed by means of the microsatellite D1S2842.
Allelic loss was scored if the area under one of the two
allelic peaks in the tumor was reduced to50%, relative
to its value in the normal tissue, thus making allowance
for any contaminating normal tissue in the sample. Loss
of the wild-type allele was found in two skin leiomy-
omata, from families 297 and 14; an example is shown
in figure 3.MCUL1 appears, therefore, to act as a tumor
suppressor, and further mapping of allelic loss may help
to refine the gene’s location.
Genetic alterations in sporadic uterine leiomyomata
appear to be few, with most studies concentrating on
deletion of chromosome 7q (Ishwad et al. 1995, 1997;
Sourla et al. 1996; Zeng et al. 1997; Sell et al. 1998;
van der Heijden et al. 1998; Vanni et al. 1999) and on
changes in the high-mobility-group genes (Hennig et al.
1996; Klotzbucher et al. 1999; Polito et al. 1999). There
are few reports of chromosome 1 alterations in sporadic
leiomyomata at any site (Polito et al. 1999), and none
of these studies has included markers in the 1q42.3-q43
region (van der Heijden et al. 1998). Gains and losses
of 1q are, however, among the most common cytogenetic
changes observed in tumors.
Multiple leiomyomatosis is a disease of benign tumors
arising from the erector pili muscles and of uterine fi-
broids. Its chief importance lies in the subfertility and
blood loss caused by the fibroids and in its role as a
model for sporadic fibroid development. We have pro-
vided evidence to show that a high-penetrance, domi-
nant gene, which we have designated “MCUL1,” pre-
disposing to multiple leiomyomata of the skin and
uterus, is located within a 14-cM interval on chromo-
some 1q42.3-q43. In this study, data for all the families
with ML were consistent with linkage to MCUL1, with
the exception of one small pedigree. It is possible that
genetic predisposition to ML is heterogeneous, but we
cannot preclude the possibility of phenocopies or di-
agnostic error in this family. Several known genes lo-
cated in the minimal MCUL1 region may be considered
candidates. These include zinc-finger protein ZNF124,
nidogen, ryanodine receptor R2, and a2-actinin. Fur-
ther studies are under way to refine the localization of
and to identify MCUL1. Identification of MCUL1
should have wide biological interest because of its pos-
sible involvement in both non-Mendelian predisposition
to uterine leiomyomata and somatic mutation in spo-
radic leiomyomata.
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